** Shares of drug developer MetaVia MTVA.O rise 17.9% to $2.17 premarket
** Co says its experimental obesity drug showed a maximum reduction of 6.3% in body weight in a 28-day, 36-patient portion of an early-stage trial
** The drug, DA-1726, on average reduced body weight by 4.3%
** Additionally, MTVA says DA-1726 showed waist circumference reduction of 1.6 inches on average, with a maximum reduction of 3.9 inches by day 33
** "We anticipate that greater weight loss may be seen in longer duration studies" - co
** In November, co changed its name to MetaVia from NeuroBo Pharmaceuticals
** Up to last close, stock had fallen 9.4% YTD
(Reporting by Puyaan Singh)
((Puyaan.Singh@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.